Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders

• US 20060128730A1
• Filed: 02/06/2006
• Published: 06/15/2006
• Est. Priority Date: 04/20/2001
• Status: Abandoned Application

• Current Assignee: Boehringer Ingelheim Pharma GmbH & Company Kg (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim Pharma GmbH & Company Kg (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Eisert, Wolfgang
• Application Number:
  US11/347,896
• Publication Number:
  US 20060128730A1
• Time in Patent Office: Days
• US Class Current: 514/262.100
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/366 having six-membered rings, e.g. delta-lactones
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

A method of treatment of the human or non-human animal body for treating NO-dependent microcirculation disorders is disclosed, for example microcirculation disorders caused by metabolic diseases, such as elevated levels of homocystin-homocystein inflammatory reactions or autoimmune diseases, furthermore peripheral microcirculation disorders or microcirculation disorders associated with increased cell fragmentation, which method comprises administering to a human or non-human animal body in need of such treatment an effective amount of a pharmaceutical composition containing a substance which scavenges free radicals, e.g. a pyrimido-pyrimidine selected from Dipyridamole, Mopidamol and the pharmaceutically acceptable salts thereof, and the use such substance for the manufacture of a corresponding pharmaceutical composition, optionally in combination with an agent capable of increasing NO procution.

Claims

1-12. -12. (canceled)

13. A pharmaceutical composition for treating NO-dependent microcirculation disorders comprising dipyridamole or a pharmaceutically acceptable salt thereof in combination with one or more HMG CoA reductase inhibitors.

14. The pharmaceutical composition of claim 13, wherein administration of the composition to an animal results in a maintained plasma level of about 0.2 to 5 μ

mol/L of dipyridamole.

15. The pharmaceutical composition of claim 13, wherein the composition is administered orally in a sustained or controlled release formulation.

16. The pharmaceutical composition of claim 13, wherein the composition is administered parenterally.

17. The pharmaceutical composition of claim 15, wherein the dipyridamole is administered orally in a daily dosage of 25 to 450 mg or parenterally in a dosage of 0.5 to 5 mg/kg body weight over 24 hours.

18. The pharmaceutical composition of claim 15 wherein the HMG CoA reductase inhibitor may be one or more selected from the group consisting of:

lovastatin,

pravastatin,

simvastatin,

fluvastatin,

dalvastatin,

compactin, mevastatin,

HR 780,

BMY 22,089,

BMY 22,566,

SQ 33,600,

GR 95,030 and

CI 981.

19. The pharmaceutical composition of claim 15 wherein the HMG CoA reductase inhibitor is selected from the group consisting of:

lovastatin,

pravastatin,

simvastatin,

fluvastatin,

dalvastatin, and

mevastatin.

20. The pharmaceutical composition of claim 15 wherein the HMG CoA reductase inhibitor is pravastatin.